Abstract Streptococcus pyogenes (Group A Streptococcus; GAS) is exquisitely adapted to
the human host, resulting in asymptomatic infection, pharyngitis, pyoderma, scarlet fever or …

Homelessness increases the risk of acquiring an infectious disease. We conducted a
systematic review of the literature to identify quantitative data related to infectious diseases …

Background Streptococcus pyogenes, or group A Streptococcus (GAS), infections contribute
to a high burden of disease in Aboriginal Australians, causing skin infections and immune …

From 2015–2018 to 2019‒2021, hypertoxigenic M1UK lineage among invasive group A
Streptococcus increased in the United States (1.7%, 21/1,230 to 11%, 65/603; p< 0.001) …

All known group A streptococci [GAS] are susceptible to β-lactam antibiotics. We recently
identified an invasive GAS (iGAS) variant (emm43. 4/PBP2x-T553K) with unusually high …

Clindamycin and β-lactam antibiotics have been mainstays for treating invasive group A
Streptococcus (iGAS) infection, yet such regimens might be limited for strains displaying …

Background Group A Streptococcus (GAS) causes multiple clinical manifestations, including
invasive (iGAS) or even life-threatening (severe-iGAS) infections. After the drop in cases …

Background Increasing incidence of invasive group A Streptococcus (iGAS) disease has
been reported in Europe and the USA over the past several years. Coupled with this are …

In many countries, iGAS rates surged from mid-2022 in the aftermath of pandemic control
measures and physical distancing. The emergence of a dominant hypervirulent strain is an …

Group A streptococcal strains potentially acquire new M protein gene types through genetic
recombination (emm switching). To detect such variants, we screened 12,596 invasive GAS …